BTMD Share Price Performance
US$2.70
-3.67 (-57.61%)
32.5% undervalued intrinsic discount
US$4.00
Fair Value
Price US$2.70
AnalystLowTarget US$4.00
AnalystHighTarget US$7.00
AnalystConsensusTarget US$4.88
Fair ValueUS$3.50
Share Pricen/a
biote Corp. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
BTMD Community Narratives
AN
Fair Value US$3.5 22.9% undervalued intrinsic discount
Regulatory Risks Will Limit Hormone Therapy But Telemedicine Will Help
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$6 55.0% undervalued intrinsic discount
Digital Health Expansion Will Elevate Preventative Care Despite Regulatory Hurdles
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$4.88 44.7% undervalued intrinsic discount
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Digital Health Expansion Will Elevate Preventative Care Despite Regulatory Hurdles
Key Takeaways Aggressive sales strategies, digital platform expansion, and e-commerce growth could accelerate provider network gains, mainstream adoption, and recurring revenue streams beyond expectations. Investment in personalized medicine, proprietary diagnostics, and international expansion could establish long-term market leadership and drive substantial improvements in margin and earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
55.0% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
8.14% p.a.
Profit Margin
1.81%
Future PE
55.77x
Price in 2028
US$7.19
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
Key Takeaways Restructuring commercial operations and expanding digital wellness products aim to accelerate clinic growth, enhance retention, and diversify revenue channels. Increased market penetration, in-house manufacturing, and improved clinic value support long-term margin gains and consistent recurring revenues.Read more
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$4.88
44.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
5.93% p.a.
Profit Margin
4.08%
Future PE
29.57x
Price in 2028
US$8.52
Regulatory Risks Will Limit Hormone Therapy But Telemedicine Will Help
Key Takeaways Heavy dependence on hormone therapy heightens risk from market shifts, regulatory scrutiny, and clinic retention challenges, potentially limiting consistent revenue and margin growth. Gains from industry trends and operational restructuring face headwinds from legal, reputational, and onboarding concerns, which could constrain long-term financial performance.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3.5
22.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
2% p.a.
Profit Margin
4.74%
Future PE
20.42x
Price in 2028
US$6.11
Trending Discussion
Recently Updated Narratives
AN
BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook
Fair Value: US$6 55.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
Fair Value: US$4.88 44.7% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Risks Will Limit Hormone Therapy But Telemedicine Will Help
Fair Value: US$3.5 22.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
biote Corp. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 0.89
- 72.37%
- 14.72%
- -157.9%
About BTMD
- Founded
- 2012
- Employees
- 217
- CEO
- WebsiteView website
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
